Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  October 15, 2018

A recent study suggests Zilretta, an intra-articular injection for OA knee pain, may lower blood glucose levels in OA patients…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:blood glucosefilgotinibKnee Osteoarthritis (OA)knee painRheumatoid Arthritis (RA)Zilretta

New Research Shows Knee Osteoarthritis Prevalence Is Rising

Mary Beth Nierengarten  |  September 20, 2018

Studies highlighting the large numbers of people affected by knee osteoarthritis (OA) point to what clinicians who treat knee OA have been seeing for the past few decades: a substantial increase in the prevalence of knee OA in the U.S. and globally. Roughly 250 million people are affected by knee OA worldwide, and about 14…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:body mass index (BMI)knee osteoarthritisphysical activity

The 2018 ACR/ARHP Annual Meeting Program Preview

From the College  |  September 20, 2018

Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…

Filed under:From the College Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)

HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?

From the College  |  September 20, 2018

Multiple studies show that hydroxychloroquine (HCQ) has many benefits in systemic lupus erythematosus (SLE), including cardiovascular benefits, such as reducing coronary artery and thrombosis risks. HCQ can prevent disease flares, including in renal and central nervous system lupus, and is the only drug shown to prolong survival in lupus. However, guidelines released in 2016 by…

Filed under:From the CollegeSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingdosageHCQHYDROXYCHLOROQUINE

Sessions to Check Out During the 2018 ACR/ARHP Annual Meeting

From the College  |  September 17, 2018

With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…

Filed under:Conditions Tagged with:2018 ACR/ARHP Annual MeetingACR/ARHP Annual Meeting

A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study

Elizabeth Hofheinz, MPH, MEd  |  August 17, 2018

“You have systemic sclerosis,” says the physician. Other somber words patients may hear the day they learn their diagnosis include, “rare, chronic, no treatment.” But a ray of hope could soon enter those exam rooms thanks to research conducted by a team from the UK. Rizgar A. Mageed, PhD, FRCP, FRCPath, is professor of experimental…

Filed under:ConditionsSystemic Sclerosis Tagged with:B lymphocytesDr. Rizgar MageedSScsystemic sclerodermaSystemic sclerosis

5 Ways to Improve Your Collaboration with Orthopedic Surgeons

Vanessa Caceres  |  August 17, 2018

Rheumatologists and orthopedic surgeons must frequently collaborate to provide optimal patient care. Sometimes, they may even work at the same practice and form a care team for easy collaboration. Still, patient management from both specialties can be challenging, and specialists from both sides can learn from each other. How Crossover Starts Rheumatologists and orthopedic surgeons…

Filed under:Patient PerspectivePractice Support Tagged with:collaborationcommunicationinterdisciplinary

Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

Carina Stanton  |  August 17, 2018

For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….

Filed under:ConditionsVasculitis Tagged with:ActemraTakayasu arteritis (TAK)tocilizumab

Upadacitinib Promising for RA Patients

Michele B. Kaufman, PharmD, BCGP  |  July 23, 2018

Upadacitinib proved safe and effective in RA patients who had inadequate responses to conventional disease-modifying anti-rheumatic drugs…

Filed under:Drug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation

Lara C. Pullen, PhD  |  June 27, 2018

Does cognitive dysfunction in SLE patients result from persistent inflammation characterized by ongoing disease activity? Recent research examining this question found no inflammatory mechanism associated with cognitive dysfunction in this patient population, underscoring previous research findings…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:cognitive dysfunctioninflammationLupusSLEsystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 64
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences